Verona Pharma Plc – Product Pipeline Review – 2012 - Global Market Direct's pharmaceuticals report, "Verona Pharma Plc - Product Pipeline Review - 2012" provides data on the Verona Pharma Plc's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from our proprietary databases, Verona Pharma Plc's corporate website, SEC filings, investor presentations and featured press releases, both from Verona Pharma Plc and industry-specific third party sources, put together by our team.
Scope
- Verona Pharma Plc - Brief Verona Pharma Plc overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Verona Pharma Plc human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Verona Pharma Plc with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Verona Pharma Plc's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Verona Pharma Plc's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Verona Pharma Plc in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Verona Pharma Plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Verona Pharma Plc.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Verona Pharma Plc and identify potential opportunities in those areas.
Table of Contents
Table of Contents
List of Tables
List of Figures
Verona Pharma Plc Snapshot
Verona Pharma Plc Overview
Key Information
Key Facts
Verona Pharma Plc – Research and Development Overview
Key Therapeutic Areas
Verona Pharma Plc – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Verona Pharma Plc – Pipeline Products Glance
Verona Pharma Plc Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Verona Pharma Plc – Early Stage Pipeline Products
Discovery Products/Combination Treatment Modalities
Verona Pharma Plc – Drug Profiles
NAIPs
Product Description
Mechanism of Action
R&D Progress
RPL-554
Product Description
Mechanism of Action
R&D Progress
VRP-700
Product Description
Mechanism of Action
R&D Progress
Verona Pharma Plc – Pipeline Products by Route of Administration
Verona Pharma Plc – Pipeline Products By Mechanism of Action
Verona Pharma Plc – Recent Pipeline Updates
Verona Pharma Plc - Dormant Projects
Verona Pharma Plc – Company Statement
Verona Pharma Plc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Verona Pharma Plc, Recent Developments
Verona Pharma Plc- Press Release
Oct 12, 2012: Verona Pharma Presents Phase I/IIa Study Data Of RPL554 At ISAF 2012
Sep 04, 2012: Verona Pharma Presents Phase II Data Of RPL554 In COPD Patients At 2012 European Respiratory Society
Aug 28, 2012: Verona Pharma Obtains US Patent For Asthma And COPD Drug Candidate RPL554
Jul 09, 2012: Verona Pharma Initiates Dosing In Clinical Trial To Investigate Anti-inflammatory Properties Of RPL554
Mar 09, 2012: Verona Pharma Signs Contract With Medicines Evaluation Unit To Carry Out First UK-Based Anti-Inflammatory Clinical Trial With RPL554
Sep 11, 2009: Verona Pharma Plc Announces Final Results Of Phase I/IIa Trial Of RPL554
May 20, 2009: First Two Stages Of RPL554 Phase I/IIa Clinical Trial Yields Positive Results, Approval to proceed to final stage of trial
Jan 28, 2009: Verona Pharma Obtains Regulatory Approval To Conduct A Clinical Trial Of Its New Anti-Asthma Drug RPL554
Financial Deals Landscape
Verona Pharma Plc, Deals Summary
Verona Pharma Plc, Pharmaceuticals & Healthcare, Deal Details
Partnerships
Verona Pharma Enters Into Co-Development Agreement With GlycoMar
Licensing Agreements
Verona Pharma Announces Licensing Agreement For RPL554
Equity Offering
Verona Pharma Completes Private Placement Of Common Stock For $5 Million
Verona Pharma Completes Public Offering Of $5 Million
Verona Pharma Completes Private Placement Of $4.71 Million
Verona Pharma Completes Private Placement Of $0.2 Million
Verona Pharma Completes Private Placement Of $2.86 Million
Acquisition
Verona Pharma Acquires Rhinopharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Verona Pharma Plc, Key Information
Verona Pharma Plc, Key Facts
Verona Pharma Plc – Pipeline by Indication, 2012
Verona Pharma Plc – Pipeline by Stage of Development, 2012
Verona Pharma Plc – Monotherapy Products in Pipeline, 2012
Verona Pharma Plc – Phase II, 2012
Verona Pharma Plc – Discovery, 2012
Verona Pharma Plc – Pipeline By Route of Administration, 2012
Verona Pharma Plc – Pipeline Products By Mechanism of Action, 2012
Verona Pharma Plc – Recent Pipeline Updates, 2012
Verona Pharma Plc - Dormant Developmental Projects,2012
Verona Pharma Plc, Subsidiaries
Verona Pharma Plc, Deals Summary
Verona Pharma Enters Into Co-Development Agreement With GlycoMar
Verona Pharma Announces Licensing Agreement For RPL554
Verona Pharma Completes Private Placement Of Common Stock For $5 Million
Verona Pharma Completes Public Offering Of $5 Million
Verona Pharma Completes Private Placement Of $4.71 Million
Verona Pharma Completes Private Placement Of $0.2 Million
Verona Pharma Completes Private Placement Of $2.86 Million
Verona Pharma Acquires Rhinopharma
List of Figures
Verona Pharma Plc – Pipeline by Indication, 2012
Verona Pharma Plc – Pipeline by Stage of Development, 2012
Verona Pharma Plc – Monotherapy Products in Pipeline, 2012
Verona Pharma Plc – Pipeline By Route of Administration, 2012
Verona Pharma Plc - Pipeline Products By Mechanism of Action, 2012 17